MetaCap

Marker Therapeutics (MRKR) vs Shuttle Pharmaceuticals (SHPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Marker Therapeutics (MRKR) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, gaining 2.8% versus a loss of 78.2%. Marker Therapeutics is the larger company by market cap ($18.2 million vs $16.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MRKR+2.83%SHPH-78.19%
+116%+12%-92%
Nov 21, 20251 yearNov 20, 2026
MRKR-63.67%SHPH-99.99%
+173%+30%-113%
Aug 29, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MRKR versus SHPH key metrics
MetricMRKRSHPH
Share price$1.09$3.49
Market cap$18.17M$16.63M
1-day change-17.42%-10.51%
YTD return-26.85%-80.61%
1-year return+2.83%-78.19%
5-year return-91.14%—
EPS (TTM)$-0.39$-16.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.55M—
Revenue growth (YoY)-46.19%—
Net income (latest FY)$-12.16M$-11.72M
Operating margin-363.45%—
Net margin-342.96%—
52-week high$2.46$44.40
52-week low$0.81$2.58
Distance from 52-week high-55.69%-92.14%
Analyst consensusnone—
Avg. price target upside+622.02%—
Average volume711.96K41.80K
Shares outstanding16.67M4.76M
Employees52
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRKR has outperformed SHPH by 81.0 percentage points over the past year.

About Marker Therapeutics

MRKR stock →

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Shuttle Pharmaceuticals

SHPH stock →

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

MRKR vs SHPH FAQ

Which is bigger, Marker Therapeutics or Shuttle Pharmaceuticals?

Marker Therapeutics (MRKR) is larger, with a market capitalization of $18.17M compared with $16.63M for Shuttle Pharmaceuticals (SHPH).

Which stock has performed better over the past year, MRKR or SHPH?

MRKR returned +2.83% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.

Are Marker Therapeutics and Shuttle Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons